Outlook Therapeutics Inc (OTLK)
$5.5
+0.19
(+3.58%)▲
Live
Performance
- $5.44$5.74$5.50
1.18%
Downside
Day's Volatility :5.23%
Upside
4.1%
- $4.61$13.32$5.50
16.18%
Downside
52 Weeks Volatility :65.4%
Upside
58.71%
Returns
| Period | Outlook Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -34.69% | 0.0% |
6 Months | -34.36% | 0.0% |
1 Year | -42.66% | 0.0% |
3 Years | -87.42% | -23.0% |
Highlights
Market Capitalization | 121.6M |
Book Value | -$3.57 |
Earnings Per Share (EPS) | -5.89 |
Wall Street Target Price | 37.2 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -83.69% |
Return On Equity TTM | -3.65% |
Revenue TTM | 5.9M |
Revenue Per Share TTM | 0.12 |
Quarterly Revenue Growth YOY | 658.3000000000001% |
Gross Profit TTM | -42.3M |
EBITDA | -61.2M |
Diluted Eps TTM | -5.89 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.11 |
EPS Estimate Next Year | -2.57 |
EPS Estimate Current Quarter | -1.01 |
EPS Estimate Next Quarter | -0.99 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 576.36%
Technicals Summary
Sell
Neutral
Buy
Outlook Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Outlook Therapeutics Inc | -4.84% | -34.36% | -42.66% | -87.42% | -78.93% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Outlook Therapeutics Inc | NA | NA | NA | -5.11 | -0.04 | -0.84 | NA | -3.57 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Outlook Therapeutics Inc | Buy | $121.6M | -78.93% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Outlook Therapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 127.8%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 132.2%
Institutional Holdings
Great Point Partners LLC
7.19%TANG CAPITAL MANAGEMENT LLC
6.85%BlackRock Inc
2.80%Sphera Funds Management Ltd.
2.42%Vanguard Group Inc
2.32%Altium Capital Management, LP
2.12%
Company Information
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Organization | Outlook Therapeutics Inc |
Employees | 24 |
CEO | Mr. Ralph H. Thurman |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$5.50
+3.58%
Invesco Bulletshares 2025 Hi
$5.50
+3.58%
Schwab International Dividend Equity Etf
$5.50
+3.58%
Blockchain Coinvestors Acquisition Corp.
$5.50
+3.58%
Allgiant Travel Company
$5.50
+3.58%
Rogers Corp
$5.50
+3.58%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$5.50
+3.58%
Iheartmedia
$5.50
+3.58%
Lightpath Technologies Inc
$5.50
+3.58%